Polyarthritis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 28 May 2026 11:29:02 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Polyarthritis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of RSV vaccines Arexvy and Abrysvo in patients with inflammatory rheumatic diseases receiving anti-rheumatic treatments https://clinicaltrials.eu/trial/study-of-rsv-vaccines-arexvy-and-abrysvo-in-patients-with-inflammatory-rheumatic-diseases-receiving-anti-rheumatic-treatments/ Wed, 29 Apr 2026 15:06:33 +0000 https://clinicaltrials.eu/trial/study-of-rsv-vaccines-arexvy-and-abrysvo-in-patients-with-inflammatory-rheumatic-diseases-receiving-anti-rheumatic-treatments/ This study focuses on patients with Inflammatory Rheumatic Disease who receive various treatments including disease modifying anti-rheumatic drugs (DMARDs) such as methotrexate, and different biological treatments like anti-TNF, anti-IL6r, anti-CD20, and JAK-inhibitors. The study will evaluate how these treatments affect the body’s response to Respiratory Syncytial Virus (RSV) vaccination.

Two different RSV vaccines will be used in the study: Arexvy and Abrysvo. Both vaccines are given as a single injection into the muscle. The purpose is to determine if the medications used to treat inflammatory rheumatic disease affect how well the body develops protection after receiving the RSV vaccine.

Participants will receive one dose of the RSV vaccine and will have blood samples taken before and after vaccination to measure their body’s immune response. The study will also monitor any side effects that may occur after vaccination. This information will help healthcare providers better understand how these treatments influence vaccine effectiveness in patients with inflammatory rheumatic disease.

]]>